Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 12/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 12/20 | 0.46 |
| ▸ | NQO2 | P16083 | 7/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | MIF | P14174 | 1/20 | 0.34 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.34 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18334479 | 0.81 | GAA (0.39) | MTNR1AMTNR1BGAADRD2DRD4 | |
| SCHEMBL18334543 | 0.80 | GAA (0.40) | MTNR1AMTNR1BGAA | |
| SCHEMBL18334537 | 0.77 | GAA (0.37) | MTNR1AMTNR1BNQO2GAAOPRD1 | |
| SCHEMBL18334461 | 0.76 | MTNR1A (0.40) | MTNR1AMTNR1BNQO2GAAOPRD1 | |
| SCHEMBL18334574 | 0.73 | MT-CO2 (0.34) | MTNR1AMTNR1BGAAITGB1ITGA5 | |
| SCHEMBL18334421 | 0.73 | MTNR1A (0.37) | MTNR1AMTNR1BNQO2GAAOPRD1 | |
| SCHEMBL18334614 | 0.70 | ITGB1 (0.36) | MTNR1AMTNR1BGAAITGB1ITGA5 | |
| SCHEMBL18334425 | 0.70 | MTNR1A (0.38) | MTNR1AMTNR1BNQO2GAAOPRD1 | |
| SCHEMBL17034884 | 0.67 | NAPRT (0.43) | MTNR1AMTNR1BNQO2GAA | |
| SCHEMBL18334499 | 0.66 | GAA (0.33) | MTNR1AMTNR1BGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170107207-A1 | AMINOPYRAZOLONE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-04-20 | — | — | US | disclosed |
| EP-3109239-A1 | AMINOPYRAZOLONE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107207-A1 | AMINOPYRAZOLONE DERIVATIVE | ATAD5, ATP1A1, TIPRL | MTNR1A 2426/4885MTNR1B 2581/4885NQO2 573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.